FINWIRES · TerminalLIVE
FINWIRES

Nintendo's Fiscal 2026 Profit Jumps 52%; Warns of Tough Year Ahead With Switch Price Hikes

作者

-- Nintendo's (TYO:7974) attributable profit grew 52% in fiscal 2026 on a blowout in sales but foresees a weaker year ahead.

The Kyoto-headquartered game manufacturer's attributable profit rose to 424.1 billion yen in the year through March 31, 2026, from 278.8 billion yen in the previous fiscal year, according to a Friday disclosure to the Tokyo Exchange.

The figure beat the 418.6 billion yen estimate by analysts at Visible Alpha.

Earnings per share jumped to 364.51 yen from 239.47 yen in the preceding year. Visible Alpha analysts estimated earnings per share at 358.51.

Revenue surged 99% to 2.313 trillion yen from 1.165 trillion yen in the previous fiscal year. Despite the surge, the figure failed to meet the forecast of 2.322 trillion yen by Visible Alpha analysts.

Dedicated video game platform sales, including hardware and software, surged 107% to 2.240 trillion yen from 1.084 trillion yen.

Hardware sales of its Pokémon Pokopia game, released in March, jumped to 19.9 million units, while its Mario Kart World software saw sales reach 14.7 million units, including bundle sales.

Sales of the Nintendo Switch, which has reached its 10th year, totaled 3.8 million units, down 65% from the 10.8 million units in fiscal 2025, the game manufacturer said.

Intellectual property sales fell 9.7% year over year to 73.5 billion yen as movie-related revenue declined.

Its spring offering, "Super Mario Galaxy Movie," grossed $800 million worldwide in its first four weeks.

For fiscal 2027, the game manufacturer forecasts net profit to plunge 27% to 310 billion yen and sales to slide 11% to 2.050 trillion yen, taking into account an impact of 100 billion yen from rising component prices, including memory, and tariffs.

Sales of the Nintendo Switch 2, which reached 19.9 million in fiscal 2026, could fall 17% to 16.5 million in fiscal 2027, still signaling "a solid level of adoption" for the device in its second year since launch, the company said.

Nintendo Switch sales are forecast to fall 47% to 2 million units in fiscal 2027, the company said.

Also on Friday, the company announced price adjustments for its Nintendo Switch and Nintendo Switch 2 consoles at home and overseas.

In Japan, effective May 25, the price of Switch 2 will increase 20% to 59,980 yen from 49,980 yen. Nintendo Switch prices will also increase across its OLED, standard and Lite variants.

In the US, Nintendo will hike the price of the Switch 2 to $499.99 from $449.99. The price adjustment for the newer console, starting Sept. 1, will also take effect in Canada and Europe.

The company retained the price of its Nintendo Switch model in the US, Canada and Europe, but warned of further price revisions for the Switch 2 and the standard Switch in other regions.

Nintendo declared a dividend of 177 yen per share, more than double the 85 yen declared in the previous fiscal year. For fiscal 2027, Nintendo could pay a dividend of 162 yen per share.

相關文章

Research

傑富瑞將德文能源的評級從“持有”上調至“買入”,並將目標價從53美元上調至62美元。

根據FactSet調查的分析師報告,德文能源(Devon Energy,股票代碼:DVN)的平均評級為“增持”,平均目標價為59.67美元。 (報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們:https://www..com/contact-us)

$DVN
Mining & Metals

Telus第一季調整後獲利略低於預期,但仍超乎預期

Telus (T.TO) 週五公佈,第一季調整後利潤略有下降,但仍超乎預期。 經調整後的淨利潤(已剔除大部分一次性項目)年減 8% 至 3.56 億加元,即每股調整後基本收益 0.23 加元,去年同期為 3.88 億加元,即每股收益 0.26 加元。 FactSet 調查的分析師此前預期每股收益為 0.22 加元。 合併營業收入和其他收入年減 1% 至 50 億加元,低於去年同期的 51 億加元,也低於分析師預期的 50.6 億加元。 Telus 表示,合併服務收入成長 1% 被行動裝置收入和其他收入的下降所抵消。 該公司報告稱,本季行動和固定用戶總數成長 26.2 萬,主要得益於新增 1.2 萬部行動電話用戶、22.9 萬台連網裝置用戶以及 2.1 萬網路用戶。 截至第一季末,Telus Health的全球醫療保健覆蓋人數為1.696億,年增9,310萬人。這一成長也反映了Telus去年5月收購Workplace Options後新增的7,930萬覆蓋率。執行長Darren Entwhistle表示,公司正在評估Telus的策略合作夥伴關係,並將把任何變現所得用於降低槓桿率。 Telus將於7月2日向6月10日登記在冊的股東派發每股0.4184加元的季度股利。 Telus另行宣布,財務長Doug French將於6月30日退休。現任Telus Digital和Telus Health財務長Gopi Chande將於7月1日接任。 French將繼續擔任顧問至7月31日,並將擔任Telus旗下鐵塔公司Terrion的董事會主席。 Telus股票在美國盤前交易中最新下跌0.06美元,至12.84美元。

$T.TO
Asia

市場動態:諾和諾德印度公司4月銷售額成長40%,此前Wegovy和Ozempic產品價格下調。

根據彭博新聞週五援引Pharmarack的數據報道,諾和諾德公司4月份在印度的糖尿病和肥胖症藥物銷量大幅增長,此前該公司下調了Wegovy和Ozempic的價格,以應對來自仿製藥索瑪魯肽療法的日益激烈的競爭。 報告指出,Wegovy、Ozempic及其合作方品牌產品的銷售量在4月季增40%,達3.2萬支。這是這家丹麥製藥集團將起始劑量價格下調至多48%後的首個完整月份。 報告也指出,受低價仿製藥索瑪魯肽的推動,印度GLP-1受體激動劑市場整體在4月環比增長56%,達到41.4萬支。禮來公司仍是印度銷量最高的GLP-1受體激動劑生產商。 諾和諾德公司尚未回覆的置評請求。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源,但可能包含傳聞和推測。準確性無法保證。)

$^BSE$^NSEI